new promising os trend: Summit’s Phase 3 global data
Explore the latest global data from Summit’s PD-1xVEGF clinical trial, revealing a new promising OS trend for patients. See how this breakthrough could change care.
pd-1 inhibitor
Read More
February 8, 2026